AstraZeneca PLC Peer Comparison

Metric Value Ranking
Market Cap $243.6 Billion 5/12 LLY
$860.1B		 JNJ
$400.0B		 ABBV
$327.9B		 MRK
$286.5B		 AZN
$243.6B		 NVS
$226.9B		 AMGN
$178.9B		 PFE
$168.6B		 SNY
$144.1B		 GILD
$104.4B		 BMY
$100.8B		 GSK
$86.5B
Gross Margin 76% 5/12 MRK
81%		 LLY
81%		 JNJ
79%		 GILD
78%		 AZN
76%		 GSK
74%		 NVS
74%		 SNY
68%		 ABBV
67%		 PFE
62%		 AMGN
61%		 BMY
56%
Profit Margin 15% 6/12 MRK
30%		 LLY
26%		 NVS
26%		 GILD
23%		 JNJ
21%		 AZN
15%		 GSK
15%		 BMY
14%		 ABBV
11%		 SNY
11%		 AMGN
9%		 PFE
0%
EBITDA margin 32% 8/12 GILD
49%		 BMY
42%		 LLY
42%		 ABBV
41%		 MRK
41%		 NVS
41%		 GSK
33%		 AZN
32%		 JNJ
29%		 PFE
27%		 SNY
26%		 AMGN
23%
Quarterly Revenue $12.9 Billion 5/12 SNY
$23.3B		 JNJ
$22.4B		 MRK
$15.8B		 PFE
$13.3B		 AZN
$12.9B		 NVS
$12.5B		 ABBV
$12.3B		 BMY
$12.2B		 LLY
$11.3B		 GSK
$10.1B		 AMGN
$8.4B		 GILD
$6.9B
Quarterly Earnings $1.9 Billion 6/12 MRK
$4.8B 		JNJ
$4.7B 		NVS
$3.2B 		LLY
$3.0B 		SNY
$2.5B 		AZN
$1.9B 		BMY
$1.7B 		GILD
$1.6B 		GSK
$1.5B 		ABBV
$1.4B 		AMGN
$746.0M 		PFE
$24.0M
Quarterly Free Cash Flow $2.5 Billion 4/12 JNJ
$4.7B 		NVS
$4.1B 		ABBV
$3.8B 		AZN
$2.5B 		MRK
$2.2B 		AMGN
$2.2B 		BMY
$2.1B 		GILD
$1.2B 		GSK
$564.1M 		LLY
$63.4M 		SNY
-$553.8M 		PFE
-$2.4B
Trailing 4 Quarters Revenue $49.1 Billion 6/12 JNJ
$86.6B		 SNY
$74.6B		 MRK
$61.4B		 PFE
$55.6B		 ABBV
$54.4B		 AZN
$49.1B		 NVS
$48.2B		 BMY
$46.5B		 GSK
$40.3B		 LLY
$38.9B		 AMGN
$30.9B		 GILD
$27.8B
Trailing 4 Quarters Earnings $6.4 Billion 5/12 SNY
$23.3B 		JNJ
$22.4B 		MRK
$15.8B 		PFE
$13.3B 		AZN
$12.9B 		NVS
$12.5B 		ABBV
$12.3B 		BMY
$12.2B 		LLY
$11.3B 		GSK
$10.1B 		AMGN
$8.4B 		GILD
$6.9B
Quarterly Earnings Growth 6% 7/12 ABBV
473% 		MRK
69% 		LLY
68% 		SNY
57% 		GILD
54% 		NVS
40% 		AZN
6% 		JNJ
-9% 		BMY
-19% 		GSK
-28% 		AMGN
-46% 		PFE
-99%
Annual Earnings Growth -11% 5/12 JNJ
670% 		NVS
76% 		LLY
27% 		SNY
6% 		AZN
-11% 		ABBV
-22% 		GSK
-34% 		AMGN
-68% 		GILD
-74% 		MRK
-81% 		PFE
-114% 		BMY
-174%
Quarterly Revenue Growth 13% 3/12 SNY
99% 		AMGN
20% 		AZN
13% 		GSK
10% 		BMY
9% 		MRK
9% 		GILD
5% 		PFE
4% 		ABBV
1% 		LLY
0% 		NVS
-10% 		JNJ
-12%
Annual Revenue Growth 12% 4/12 LLY
86% 		SNY
57% 		AMGN
22% 		AZN
12% 		GSK
12% 		MRK
10% 		GILD
8% 		BMY
3% 		ABBV
-6% 		NVS
-10% 		JNJ
-13% 		PFE
-18%
Cash On Hand $6.9 Billion 6/12 JNJ
$24.9B 		ABBV
$18.1B 		AMGN
$9.3B 		NVS
$7.9B 		SNY
$7.5B 		AZN
$6.9B 		BMY
$6.3B 		MRK
$5.7B 		GSK
$3.8B 		LLY
$3.2B 		GILD
$2.8B 		PFE
$1.1B
Short Term Debt $5.4 Billion 7/12 PFE
$11.9B 		SNY
$10.5B 		ABBV
$10.2B 		JNJ
$9.9B 		NVS
$7.8B 		AMGN
$5.5B 		AZN
$5.4B 		LLY
$5.2B 		GSK
$4.3B 		BMY
$3.7B 		MRK
$3.1B 		GILD
$1.8B
Long Term Debt $27.2 Billion 7/12 ABBV
$63.8B		 PFE
$57.5B		 AMGN
$57.1B		 BMY
$48.9B		 JNJ
$31.6B		 MRK
$31.1B		 AZN
$27.2B		 LLY
$23.7B		 GILD
$21.5B		 NVS
$19.7B		 GSK
$17.4B		 SNY
$13.7B
PE 37.83 6/12 MRK
124.26		 LLY
117.15		 GILD
99.19		 AMGN
57.15		 ABBV
54.72		 AZN
37.83		 GSK
16.74		 SNY
16.65		 NVS
14.03		 JNJ
10.52		 PFE
-1.00		 BMY
-1.00
PS 4.96 4/12 LLY
22.10		 ABBV
6.03		 AMGN
5.79		 AZN
4.96		 NVS
4.71		 MRK
4.67		 JNJ
4.62		 GILD
3.76		 PFE
3.03		 BMY
2.17		 SNY
1.76		 GSK
1.67
PB 6.15 5/12 LLY
63.08		 ABBV
40.75		 AMGN
30.19		 MRK
7.09		 AZN
6.15		 BMY
5.91		 GILD
5.74		 JNJ
5.59		 NVS
5.41		 GSK
4.90		 PFE
1.92		 SNY
1.80
PC 35.23 5/12 LLY
266.82		 PFE
160.25		 MRK
50.53		 GILD
37.68		 AZN
35.23		 NVS
28.71		 GSK
22.79		 SNY
19.29		 AMGN
19.23		 ABBV
18.15		 JNJ
16.08		 BMY
16.02
Liabilities to Equity 1.64 7/12 ABBV
17.59		 AMGN
14.34		 BMY
4.56		 LLY
4.29		 GSK
3.08		 GILD
1.94		 AZN
1.64		 MRK
1.62		 JNJ
1.53		 PFE
1.46		 NVS
1.33		 SNY
0.78
ROA 0.06 6/12 JNJ
21% 		NVS
17% 		LLY
10% 		GSK
9% 		SNY
7% 		AZN
6% 		ABBV
4% 		AMGN
3% 		GILD
2% 		MRK
2% 		PFE
-1% 		BMY
-7%
ROE 0.16 7/12 ABBV
75% 		LLY
54% 		JNJ
53% 		AMGN
53% 		NVS
39% 		GSK
36% 		AZN
16% 		SNY
12% 		GILD
6% 		MRK
6% 		PFE
-3% 		BMY
-38%
Current Ratio 1.61 6/12 SNY
2.29		 NVS
1.75		 PFE
1.69		 JNJ
1.65		 MRK
1.62		 AZN
1.61		 GILD
1.51		 GSK
1.31		 LLY
1.23		 BMY
1.22		 AMGN
1.07		 ABBV
1.06
Quick Ratio 0.11 6/12 MRK
124.26		 LLY
117.15		 GILD
99.19		 AMGN
57.15		 ABBV
54.72		 AZN
37.83		 GSK
16.74		 SNY
16.65		 NVS
14.03		 JNJ
10.52		 PFE
-1.00		 BMY
-1.00
Long Term Debt to Equity 0.69 8/12 AMGN}
9.64		 ABBV}
7.97		 BMY}
2.87		 LLY}
1.75		 GILD}
1.18		 GSK}
0.94		 MRK}
0.77		 AZN}
0.69		 PFE}
0.66		 NVS}
0.47		 JNJ}
0.44		 SNY}
0.17
Debt to Equity 0.85 7/12 AMGN
10.57		 ABBV
9.24		 BMY
3.17		 LLY
2.13		 GILD
1.28		 GSK
1.18		 AZN
0.85		 MRK
0.85		 PFE
0.79		 NVS
0.69		 JNJ
0.58		 SNY
0.33
Burn Rate 13.78 2/12 SNY
16.54		 AZN
13.78		 BMY
5.24		 ABBV
4.84		 AMGN
3.18		 PFE
0.20		 MRK
-2.06		 LLY
-4.43		 GILD
-9.24		 NVS
-15.24		 GSK
-24.84		 JNJ
-26.00
Cash to Cap 0.03 7/12 BMY
0.06		 ABBV
0.06		 JNJ
0.06		 AMGN
0.05		 SNY
0.05		 GSK
0.04		 AZN
0.03		 GILD
0.03		 NVS
0.03		 MRK
0.02		 PFE
0.01		 LLY
0.00
CCR 1.31 3/12 AMGN
2.98		 ABBV
2.81		 AZN
1.31		 NVS
1.28		 BMY
1.23		 JNJ
0.99		 GILD
0.74		 MRK
0.47		 GSK
0.38		 LLY
0.02		 SNY
-0.22		 PFE
-100.79
EV to EBITDA 65.61 5/12 LLY}
187.72		 AMGN}
121.65		 ABBV}
75.82		 PFE}
65.65		 AZN}
65.61		 JNJ}
64.52		 NVS}
48.72		 MRK}
48.60		 GSK}
47.61		 GILD}
36.97		 SNY}
32.26		 BMY}
28.87
EV to Revenue 5.50 4/12 LLY
22.76		 AMGN
7.52		 ABBV
7.06		 AZN
5.50		 NVS
5.14		 MRK
5.13		 JNJ
4.81		 GILD
4.50		 PFE
4.26		 BMY
3.19		 GSK
3.10		 SNY
2.35

Cookies

We use cookies to offer a better browsing experience. Cookies enhance site navigation, analyze site usage, and assist in our marketing efforts. By clicking Accept. you agree to the storing of cookies on your device. To refuse all non-required cookies, click on Decline.

Accept View Terms & Conditions